2.Clinical Study of Ectopic Pregnancy.
Byung Wook JUNG ; Jong Dae KIM ; Eun Chul JANG ; Eun Sik SON ; Ho Joon CHOI ; Seung Gwon SHIN
Korean Journal of Obstetrics and Gynecology 2000;43(12):2159-2165
No abstract available.
Female
;
Pregnancy
;
Pregnancy, Ectopic*
3.A case of megacolon complicating pregnancy.
Gyung An HAN ; Min Jung SEO ; Jee Gwon PARK ; Sung Jae LEE ; Won Joon CHOI ; Soon Ae LEE ; Jong Hak LEE ; Won Young BAEK
Korean Journal of Obstetrics and Gynecology 2000;43(12):2319-2322
No abstract available.
Megacolon*
;
Pregnancy*
4.Effects of oral iron chelator deferasirox on human malignant lymphoma cells.
Jong Gwon CHOI ; Jung Lim KIM ; Joohee PARK ; Soonwook LEE ; Seh Jong PARK ; Jun Suk KIM ; Chul Won CHOI
Korean Journal of Hematology 2012;47(3):194-201
BACKGROUND: Iron is essential for cell proliferation and viability. It has been reported that iron depletion by a chelator inhibits proliferation of some cancer cells. Deferasirox is a new oral iron chelator, and a few reports have described its effects on lymphoma cells. The goal of this study was to determine the anticancer effects of deferasirox in malignant lymphoma cell lines. METHODS: Three human malignant lymphoma cell lines (NCI H28:N78, Ramos, and Jiyoye) were treated with deferasirox at final concentrations of 20, 50, or 100 microM. Cell proliferation was evaluated by an MTT assay, and cell cycle and apoptosis were analyzed by flow cytometry. Western blot analysis was performed to determine the relative activity of various apoptotic pathways. The role of caspase in deferasirox-induced apoptosis was investigated using a luminescent assay. RESULTS: The MTT assay showed that deferasirox had dose-dependent cytotoxic effects on all 3 cell lines. Cell cycle analysis showed that the sub-G1 portion increased in all 3 cell lines as the concentration of deferasirox increased. Early apoptosis was also confirmed in the treated cells by Annexin V and PI staining. Western blotting showed an increase in the cleavage of PARP, caspase 3/7, and caspase 9 in deferasirox-treated groups. CONCLUSION: We demonstrated that deferasirox, a new oral iron-chelating agent, induced early apoptosis in human malignant lymphoma cells, and this apoptotic effect is dependent on the caspase-3/caspase-9 pathway.
Annexin A5
;
Apoptosis
;
Benzoates
;
Blotting, Western
;
Caspase 9
;
Cell Cycle
;
Cell Line
;
Cell Proliferation
;
Flow Cytometry
;
Humans
;
Iron
;
Lymphoma
;
Triazoles
5.A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer.
Jong Gwon CHOI ; Jae Hong SEO ; Sang Cheul OH ; Chul Won CHOI ; Jun Suk KIM
Cancer Research and Treatment 2012;44(2):127-132
PURPOSE: The purpose of this study was to determine the efficacy and safety of treatment using gemcitabine and capecitabine for patients with advanced pancreatic cancer. MATERIALS AND METHODS: Patients with advanced unresectable pancreatic adenocarcinoma were enrolled in the study. Inclusion criteria included no prior systemic chemotherapy or radiation therapy, at least one radiographically documented and measurable tumor lesion, and adequate patient organ functions. The patients received 1,000 mg/m2 gemcitabine intravenously on days 1, 8 and 15, and 830 mg/m2 of oral capecitabine twice a day on days 1-21 of a 28-day cycle. RESULTS: Fifty patients with a median age of 53 years (range, 39 to 76 years) were enrolled in the study. The median follow-up was 10.0 months. The objective response rate of the 50 patients was 48.0% (95% CI, 22.5 to 57.1%). The median time to progression and overall survival were 6.5 months (95% CI, 2.3 to 8.7 months) and 10.0 months (95% CI, 5.7 to 16.7 months), respectively. Grade 3-4 toxicities associated with chemotherapy included neutropenia (22%), anemia (8%), thrombocytopenia (6%), and hand-foot syndrome (10%). CONCLUSION: Combination chemotherapy using gemcitabine and capecitabine was well tolerated and demonstrated promising efficacy in the treatment of advanced pancreatic cancer.
Adenocarcinoma
;
Anemia
;
Deoxycytidine
;
Drug Therapy, Combination
;
Fluorouracil
;
Follow-Up Studies
;
Hand-Foot Syndrome
;
Humans
;
Neutropenia
;
Pancreatic Neoplasms
;
Thrombocytopenia
;
Capecitabine
6.Induction of Humoral Immue Response in Mice by Wild and Mutant Type HBV Core DNA Vaccination.
Soo Jung YOON ; Young Sun LEE ; Taek Gyu GWON ; Joon Ho BAE ; Min Ae JANG ; Yoon Jung CHOI ; Young Ho KIM ; Min Ho SEO ; Sung Il SEO ; Won Gee BAEK ; Byung Gil CHOI ; Jong Wook PARK
Korean Journal of Immunology 2000;22(3):149-156
No abstract available.
Animals
;
DNA*
;
Mice*
;
Vaccination*
7.Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients
Yeonjoo CHOI ; Bhumsuk KEAM ; Miso KIM ; Shinkyo YOON ; Dalyong KIM ; Jong Gwon CHOI ; Ja Young SEO ; Inkeun PARK ; Jae Lyun LEE
Cancer Research and Treatment 2019;51(4):1549-1556
PURPOSE: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genetic syndrome resulting from germline mutations in fumarate hydratase. The combination of bevacizumab plus erlotinib showed promising interim results for HLRCC-associated RCC. Based on these results, we analyzed the outcome of bevacizumab plus erlotinib in Korean patients with HLRCC-associated RCC. MATERIALS AND METHODS: We retrospectively reviewed the efficacy and safety of bevacizumab plus erlotinib in patients with HLRCC-associated RCC who were confirmed to have germline mutations in fumarate hydratase. The primary endpoint was the objective response rate (ORR), while the secondary endpoints were progression-free survival (PFS) and overall survival (OS). RESULT: We identified 10 patients with advanced HLRCC-associated RCC who received bevacizumab plus erlotinib. Median age at diagnosis was 41 years, and five of the patients had received the combination as first- or second-line treatments. The ORR was 50% and the median PFS and OS were 13.3 and 14.1 months, respectively. Most adverse events were predictable and manageable by conventional measures, except for one instance where a patient died of gastrointestinal bleeding. CONCLUSION: This is the first real-world outcome of the treatment of advanced HLRCC-associated RCC. Bevacizumab plus erlotinib therapy showed promising activity with moderate toxicity. We should be increasingly aware of HLRCC-associated RCC and bevacizumab plus erlotinib should be a first-line treatment for this condition, unless other promising data are published.
Bevacizumab
;
Carcinoma, Renal Cell
;
Diagnosis
;
Disease-Free Survival
;
Erlotinib Hydrochloride
;
Fumarate Hydratase
;
Germ-Line Mutation
;
Hemorrhage
;
Humans
;
Leiomyomatosis
;
Retrospective Studies
8.Duodenal Variceal Bleeding Treated with a Transjugular Intrahepatic Portosystemic Shunt.
Young Soo KIM ; Hyung Gil KIM ; Won CHOI ; Don Haeng LEE ; Pum Soo KIM ; In Han KIM ; Jae Nam CHANG ; Hyun Joo SHIN ; Jong Gil YOO ; Sung Gwon KANG
Korean Journal of Gastrointestinal Endoscopy 1999;19(2):281-286
Most cases of upper gastrointestinal bleeding in patients with portal hypertension are caused by esophagogastric varices. Less often, bleeding originates in varices located elsewhere. If ectopic varices are found, the same hemostatic technique tend to be used. However, there is no evidence that such techniques are useful in these cases. Duodenal varices are quite common, although they rarely bleed due to their location deep in the duodenal wall. Consequently, if emergency endoscopy is not conducted, hemorrhage may be wrongfully attributed to coexisting esophagogastric varices in a patient with portal hypertension without active bleeding. Hemorrhage from duodenal varices may be severe and life threatening. We report a patient with portal hypertension and bleeding duodenal varices caused by cirrhosis of the liver. Hemorrhage was subsequently controlled by placement of a transjugular intrahepatic portosystemic shunt. We recommend that in patients with life-threatening hemorrhage from duodenal varices caused by cirrhosis of the liver, transjugular intrahepatic portosystemic shunt (TIPS) be considered in the man-agement.
Emergencies
;
Endoscopy
;
Esophageal and Gastric Varices*
;
Fibrosis
;
Hemorrhage
;
Hemostatic Techniques
;
Humans
;
Hypertension, Portal
;
Liver
;
Portasystemic Shunt, Surgical*
;
Varicose Veins
9.Percutaneous Endovascular Stent-Graft Treatment of Aortic Aneurysms and Dissections: New Techniques and Initial Experience.
Do Yun LEE ; DongHoon CHOI ; Sung Gwon KANG ; Je Whan WON ; Kwang Hoon LEE ; Jong Yun WON ; Ho Young SONG
Journal of the Korean Radiological Society 2003;48(1):13-21
PURPOSE: To evaluate the feasibility, safety and effectiveness of a newly designed percutaneously implanted separate stent-graft (SSG) for the treatment of aortic aneurysms and dissections. MATERIALS AND METHODS: Using a percutaneous technique, SSG placement (in the descending thoracic aorta in 26 cases and infrarenal abdominal aorta in 24) was attempted in 50 patients with aortic aneurysms (n=27) or dissection (n=23). All SSGs were individually constructed using self-expandable nitinol stents and a Dacron graft, and were introduced through a 12 F sheath and expanded to a diameter of 20-34 mm. In all cases, vascular access was through the femoral artery. The clinical status of each patient was monitored, and postoperative CT was performed within one week of the procedure and at 3-6 month intervals afterwards. RESULTS: Endovascular stent-graft deployment was technically successful in 49 of 50 patients (98%). The one failure was due to torsion of the unsupported graft during deployment. Successful exclusion of aneurysms and the primary entry tears of dissections was achieved in all but three patients with aortic dissection. All patients in whom technical success was achieved showed complete thrombosis of the thoracic false lumen or aneurysmal sac, and the overall technical success rate was 92%. In addition, sixteen patients demonstrated complete resolution of the dissected thoracic false lumen (n=9) or aneurysmal sac (n=7). Immediate post-operative complications occurred at the femoral puncture site in one patient with an arteriovenous fistula, and in two, a new saccular aneurysm developed at the distal margin of the stent. No patient died, and there was no instance of paraplegia, stroke, side-branch occlusion or infection during the subsequent mean follow-up period of 9.4 (range, 2 to 26) months. CONCLUSION: In patients with aortic aneurysm and dissection, treatment with a separate percutaneously inserted stent-graft is technically feasible, safe, and effective.
Aneurysm
;
Aorta, Abdominal
;
Aorta, Thoracic
;
Aortic Aneurysm*
;
Arteriovenous Fistula
;
Femoral Artery
;
Follow-Up Studies
;
Humans
;
Paraplegia
;
Polyethylene Terephthalates
;
Punctures
;
Stents
;
Stroke
;
Thrombosis
;
Transplants
10.Left ventricular muscle mass regression after aortic valve replacement.
Jae Won LEE ; Kang Ju CHOI ; Sang Gwon LEE ; Suk Jung CHOO ; Jong Ook KIM ; Duk Hyun KANG ; Jae Kwan SONG ; Meong Gun SONG
Journal of Korean Medical Science 1999;14(5):511-519
Implanting a valve that will reduce left ventricular mass is critical in aortic stenosis. Regression of left ventricular hypertrophy in 46 aortic valve replacement (AVR) patients receiving a St. Jude Medical (SJM) valve was assessed by serial electrocardiographic and echocardiographic studies during the preoperative, immediate, and late postoperative periods. The patients were divided into three groups according to valve size; 19 mm group (n=9), 21 mm group (n=20), and 23+mm group (n=17). There was no surgical mortality. The NYHA functional class improved from an average of 2.2+/-0.8 preoperatively to 1.3+/-0.5 post-operatively. Left ventricular muscle mass index (LVMI) regression failed to reach statistical significance in the 19 mm group, whereas in the other two groups a steady decrease in the LVMI occurred with follow up. ECG findings were less remarkable showing insignificant differences in voltage among the three groups (p=0.000). In conclusion, the current data suggest that the 19 mm SJM valve may not result in satisfactory left ventricular muscle mass regression despite adequate function, even in small patients. Therefore, additional procedures to accommodate a larger valve may be warranted in the aortic annulus smaller than 21 mm.
Adult
;
Aged
;
Aortic Valve/ultrasonography
;
Aortic Valve Stenosis/surgery*
;
Aortic Valve Stenosis/complications
;
Echocardiography
;
Electrocardiography
;
Female
;
Follow-Up Studies
;
Heart Valve Prosthesis*
;
Human
;
Hypertrophy, Left Ventricular/prevention & control*
;
Hypertrophy, Left Ventricular/etiology
;
Hypertrophy, Left Ventricular/diagnosis
;
Male
;
Middle Age
;
Multivariate Analysis
;
Postoperative Period
;
Remission Induction
;
Risk Factors
;
Treatment Outcome